Patient Enrolment Completed for EFTISARC-NEO Phase II Trial

Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced the successful completion of patient enrolment in its Phase II EFTISARC-NEO trial, which is exploring the efficacy of eftilagimod alpha (efti) in conjunction with radiotherapy and KEYTRUDA® (pembrolizumab) for patients diagnosed with resectable soft tissue sarcoma (STS). Conducted at the Maria Sk?odowska-Curie National Research Institute of Oncology in Warsaw, Poland, the trial has met its target with 40 patients enrolled.

Noteworthy preliminary results were shared at the Connective Tissue Oncology Society's Annual Meeting in November 2024, reflecting a significant therapeutic impact. Among 21 patients assessed for the primary endpoint, the combination therapy demonstrated a remarkable over three-fold increase in tumor hyalinization and fibrosis—median rates jumped from a historical 15% to 50% at surgical resection. This early surrogate marker is linked to improved survival outcomes in STS patients. Crucially, no grade 3 or higher toxicities related to efti or pembrolizumab were reported, indicating a favorable safety profile.

Data updates from the EFTISARC-NEO trial are anticipated in 2025, as promising results may inform future treatments in the field of oncology. Immutep continues to focus on its mission to innovate in the immunotherapy space, leveraging its expertise in Lymphocyte Activation Gene-3 (LAG-3) to enhance patient care and shareholder value.

For additional details about the trial, prospective participants and healthcare professionals can visit clinicaltrials.gov (NCT06128863). As the biotech landscape evolves, Immutep's advancements could play a significant role in the treatment of soft tissue sarcoma and beyond.

Immutep Limited’s completion of patient enrolment for the EFTISARC-NEO Phase II trial marks a significant milestone for the company, presenting a notable opportunity for investors. The trial aims to evaluate the efficacy of eftilagimod alpha (efti) in combination with radiotherapy and KEYTRUDA® (pembrolizumab) for treating resectable soft tissue sarcoma (STS). Achieving the target of 40 patients is an important step toward validating the trial's hypothesis and generating pivotal data.

The preliminary findings presented at the Connective Tissue Oncology Society (CTOS) Annual Meeting are particularly encouraging. A greater than three-fold increase in tumour hyalinization/fibrosis compared to historical controls indicates that the triple therapy may enhance patient outcomes significantly. The absence of grade 3 toxicities related to efti and pembrolizumab adds further credibility to its safety profile, which investors will likely view positively. Positive outcomes from the trial could position Immutep favorably within the highly competitive oncology landscape, especially considering the rising interest and demand for innovative cancer therapies.

Expectations for further data updates in 2025 will serve as critical catalysts for stock movement. Investors should monitor the market sentiment and any regulatory developments closely, as they could impact the valuation of Immutep's stock. Additionally, given that the successful advancement of the EFTISARC-NEO trial may enhance collaboration opportunities with larger pharmaceutical firms, the long-term outlook remains promising.

Overall, this trial's developments represent a compelling point for investment consideration. Stakeholders should remain vigilant in tracking the outcomes and subsequent advancements from Immutep, as they may yield significant returns amid the broader momentum in biopharma and immunotherapy advancements.